Proteomics in graft-versushost disease and graftversus-leukemia - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 470

[33] Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of
cancer. J Natl Cancer Inst 2001;93:1054-61.
[34] Mischak H, Allmaier G, Apweiler R, et al. Recommendations for biomarker identification
and qualification in clinical proteomics. Sci Transl Med 2010;2; 46ps42.
[35] von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) statement: guidelines for reporting observational
studies. Lancet 2007;370:1453-7.
[36] Bossuyt PM, Reitsma JB. Standards for reporting of diagnostic A: the STARD initiative.
Lancet 2003;361:71.
[37] Gu W, Pepe MS. Estimating the diagnostic likelihood ratio of a continuous marker. Bio-
statistics 2011;12:87-101.
[38] Baker SG. The central role of receiver operating characteristic (ROC) curves in evaluating
tests for the early detection of cancer. J Natl Cancer Inst 2003;95:511-5.
[39] Pepe MS, Longton G. Standardizing diagnostic markers to evaluate and compare their
performance. Epidemiology 2005;16:598-603.
[40] Schlatzer DM, Dazard JE, Ewing RM, et al. Human biomarker discovery and predictive
models for disease progression for idiopathic pneumonia syndrome following allogeneic
stem cell transplantation. Mol Cell Proteomics 2012;11; M111.015479.
[41] Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured
during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical
Trials Network study. Blood 2012;119:3854-60.
[42] Choi SW, Kitko CL, Braun T, et al. Change in plasma tumor necrosis factor receptor 1
levels in the first week after myeloablative allogeneic transplantation correlates with
severity and incidence of GVHD and survival. Blood 2008;112:1539-42.
[43] Wulfsohn MS, Tsiatis AA. A joint model for survival and longitudinal data measured with
error. Biometrics 1997;53:330-9.
[44] Paczesny S, Hanauer D, Sun Y, Reddy P. New perspectives on the biology of acute GVHD.
Bone Marrow Transplant 2010;45:1-11.
[45] Toubai T, Tanaka J, Paczesny S, Shono Y, Reddy P, Imamura M. Role of cytokines in the
pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cyto-
kines potential biomarkers for diagnosis of acute GVHD following allogeneic hemato-
poietic cell transplantation (Allo-HCT)? Curr Stem Cell Res Ther 2012;7:
229-39.
[46] Foley R, Couban S, Walker I, et al. Monitoring soluble interleukin-2 receptor levels in
related and unrelated donor allogeneic bone marrow transplantation. Bone Marrow
Transplant 1998;21:769-73.
[47] Miyamoto T, Akashi K, Hayashi S, et al. Serum concentration of the soluble interleu-
kin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant
1996;17:185-90.
[48] Seidel C, Ringdén O, Remberger M. Increased levels of syndecan-1 in serum during
acute graft-versus-host disease. Transplantation 2003;76:423-6.
[49] Shaiegan M, Iravani M, Babaee G, Ghavamzadeh A. Effect of IL-18 and sIL2R on aGVHD
occurrence after hematopoietic stem cell transplantation in some Iranian patients.
Transplant Immunol 2006;15:223-7.
[50] Visentainer JEL, Lieber SR, Persoli LBL, et al. Serum cytokine levels and acute graft-
versus-host disease after HLA-identical hematopoietic stem cell transplantation. Exp
Hematol 2003;31:1044-50.
[51] Abdallah AN, Boiron JM, Attia Y, Cassaigne A, Reiffers J, Iron A. Plasma cytokines in graft
vs host disease and complications following bone marrow transplantation. Hematol Cell
Ther 1997;39:27-32.
[52] Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha
precede major complications of bone marrow transplantation. Blood 1990;75:
1011-6.
[53] Schots R, Kaufman L, Van Riet I, et al. Proinflammatory cytokines and their role in the
development of major transplant-related complications in the early phase after alloge-
neic bone marrow transplantation. Leukemia 2003;17:1150-6.
[54] August KJ, Chiang KY, Bostick RM, et al. Biomarkers of immune activation to screen for
severe, acute GVHD. Bone Marrow Transplant 2011;46:601-4.
[55] Paczesny S, Choi SW, Ferrara JL. Acute graft-versus-host disease: new treatment strate-
gies. Curr Opin Hematol 2009;16:427-36.
[56] Schots R, Van Riet I, Othman TB, et al. An early increase in serum levels of C-reactive
protein is an independent risk factor for the occurrence of major complications and 100-
day transplant-related mortality after allogeneic bone marrow transplantation. Bone
Marrow Transplant 2002;30:441-6.
[57] Malone FR, Leisenring WM, Storer BE, et al. Prolonged anorexia and elevated plasma
cytokine levels following myeloablative allogeneic hematopoietic cell transplant. Bone
Marrow Transplant 2007;40:765-72.

476